Opportunities in pharma M&A are increasing, but competition for attractive assets is intensifying, especially for large acquirers. Winning dealmakers aim to be the acquirer of choice in multi-bidder situations by building world-class M&A organizations that can pursue scale, scope, and capability deals both proactively and reactively. Success requires acting quickly, having a clear M&A strategy, and maintaining access to capital to compete effectively on price. Companies that plan for both scale and scope acquisitions invest more heavily in dedicated M&A teams and tend to achieve stronger revenue growth, positioning themselves to secure the right deals in a complex environment.

Join for free to read